A diabetes drug may beat costly shots for patients with a rare genetic condition, according to a Rutgers Health study.

FDA formally announced the end of the tirzepatide shortage in a Declaratory Order issued to Eli Lilly & Co. (“Lilly”). Lilly ...

Results from a case series identified a potential association between ophthalmic complications and the rapid correction of hyperglycemia, brought on by patients using either semaglutide or tirzepatide ...

Jessica DeBenedetto has only been on compounded tirzepatide for a couple of weeks, but she already feels like it's a ...

Kournikova, who stays mostly out of the spotlight, has been with singer Enrique Iglesias since 2001. President Trump and Elon ...

Leerink Partners analyst David Risinger maintained a Buy rating on Eli Lilly & Co (LLY – Research Report) on January 24 and set a price ...

LEXX READ THE FULL LEXX RESEARCH REPORT Lexaria Bioscience Corporation (NASDAQ:LEXX) reported fiscal first quarter 2025 ...

Hims & Hers may leverage FDA compounding exemptions to further extend its compounded GLP-1 offerings. Learn why HIMS stock is ...

T he newest weight-loss drugs, Wegovy and Zepbound, are incredibly popular. But doctors are still learning about all of the ...

This year, revolutionary anti-obesity drugs Wegovy and Ozempic (manufactured by Danish drugmaker Novo Nordisk), and Eli Lilly ...

As evidence has mounted that new diabetes and weight loss drugs can provide a variety of health benefits, the FDA has ...

Lean mass constituted 30.8% of total body weight lost for adults who received a GLP-1 drug during a randomized controlled ...